Tomohiko Maehama

9.4k citations
66 papers · 7.6k indexed · 3 hit papers · h-index 32
Topics
PI3K/AKT/mTOR signaling in cancer (19 papers)Hippo pathway signaling and YAP/TAZ (15 papers)Protein Kinase Regulation and GTPase Signaling (14 papers)
Partner nations
JapanUnited StatesCanada

In The Last Decade

Tomohiko Maehama

65 papers receiving 7.5k citations

Hit Papers

The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Li...199820262007201619981999200050010001.5k2.0k2.5k

Peers

Tomohiko Maehama
Comparison fields: 5 of 120
  • Molecular Biology 6.2k
  • Cell Biology 1.5k
  • Oncology 1.1k
  • Immunology 937
  • Cancer Research 798
Replace Anke Klippel with:
Anke Klippel United States
Peter M. Finan United Kingdom
Estela Jacinto United States
Christian Rommel United States
Ned Lamb France
Robert Latek United States
Claudio Sette Italy
John Manis United States
Kent L. Rossman United States
Shubha Bagrodia United States
Tomohiko Maehama relative to Anke Klippel United States Anke Klippel's profile →
Citations per field
00.5×
Anke Klippel · 1×
Citations per year

Countries citing papers authored by Tomohiko Maehama

Since Specialization
Citations

This map shows the geographic impact of Tomohiko Maehama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomohiko Maehama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomohiko Maehama more than expected).

Fields of papers citing papers by Tomohiko Maehama

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomohiko Maehama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomohiko Maehama. The network helps show where Tomohiko Maehama may publish in the future.

Co-authorship network of co-authors of Tomohiko Maehama

This figure shows the co-authorship network connecting the top 25 collaborators of Tomohiko Maehama. A scholar is included among the top collaborators of Tomohiko Maehama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomohiko Maehama. Tomohiko Maehama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 14
2 24
3 91
4 11
5 49
6 1
7 27
8 60
9 11
10 41
11 27
12 66
13 86
14 102
15
The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphatebreakdown →
2551
16 229
17 1
18 17
19 38
20 1

About Tomohiko Maehama

Tomohiko Maehama is a scholar working on Physiology, Cell Biology and Molecular Biology, having authored 66 papers that have together received 7.6k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (19 papers), Hippo pathway signaling and YAP/TAZ (15 papers) and Protein Kinase Regulation and GTPase Signaling (14 papers). The work is most often cited by research in Molecular Biology (6.2k citations), Cell Biology (1.5k citations) and Aging (95 citations). Tomohiko Maehama has collaborated with scholars based in Japan, United States and Canada. Frequent co-authors include Jack E. Dixon, Gregory S. Taylor, Brian A. Hemmings, Marco Muda, Carolyn A. Worby, James C. Clemens, Yasunori Kanaho, Nikola P. Pavletich, Maria-Magdalena Georgescu and Yigong Shi. Their work appears in journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026